Type I IFN responses (characterized by low IFN-α and no IFN-β production and activity) are severely impaired in critically ill patients with COVID-19, resulting in exacerbated inflammatory responses and persistent blood viral loads (Hadjadj et al., 2020). Here, IFNB1 is linked to COVID-19.